Compare Moderna, Inc. (MRNA) vs Annaly Capital Management, Inc. (NLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Annaly Capital Management, Inc. — how do they compare? Moderna, Inc. trades at $135.93 (market cap $56.02B), while Annaly Capital Management, Inc. trades at $22.83 (market cap $17.12B). The key difference: Moderna, Inc. is far larger — about 3.3× Annaly Capital Management, Inc.'s market cap, and Annaly Capital Management, Inc. pays a 13.2% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | NLY | |
|---|---|---|
Market Cap | $56.02B | $17.12B |
Sector | Health | Financials |
52-Week High | $174.38 | $24.40 |
52-Week Low | $22.36 | $20.21 |
Enterprise Value | $52.17B | — |
Dividend Yield | — | 13.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, but maintains a bullish technical signal with support at $138 and resistance at $145. Recent positive phase 3 cancer vaccine trial results have driven significant stock appreciation, though financials show declining revenue and negative net income margins. The company has beaten EPS estimates for the last three quarters, with Q3 2026 results pending.
The outlook is mixed; promising clinical developments in oncology offer long-term growth potential, but high valuation multiples and persistent losses pose risks. Analyst consensus is cautious with a $90.08 price target below the current price, reflecting concerns over profitability and competitive pressures in the mRNA therapeutics space.
NLY trades at $22.72, down 0.39% today, with a technical bearish signal but strong fundamentals including a P/E of 5.49 and ROE of 20.66%. Recent earnings beats and a $0.75 dividend highlight operational strength, though cash flow volatility and high leverage pose risks.
Outlook remains positive with analyst consensus at Buy (57% of 28 analysts) and a $24.33 price target, offering ~7% upside. Key risks include interest rate sensitivity and debt levels, but diversified mortgage assets and consistent dividend coverage support income appeal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →
